Bibliography
- ARRANG JM, GARBURG M, SCHWARTZ JC: Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature (1983) 302:832–837.
- SCHLICKER E, BETZ R, GOTHERT M:Histamine H3 receptor-mediated inhibition of release in the rat brain cortex. Naunyn Schmedebergs Arch. Pharmacol (1988) 337:588–590.
- SCHLICKER E, FINK K, HINTERTHANER M, GOTHERT M: Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors. Naunyn Schmedebergs Arch. Pharmacol (1989) 340:633–638.
- SCHLICKER E, FINK K, DETZNER M, GOTHERT M: Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J. Neural Transm. (1993) 93:1–10.
- LEURS R, SMIT MJ, TIMMERMAN H: Molecular pharmacological aspects of histamine receptors. Pharmacol Ther. (1995) 66:413–363.
- LOVENBERG TW, POLAND B, WILSON S et al.: Cloning and functional expression of the human H3 receptor. Mol PharmacoL (1999) 55:1101–1107.
- WELLENDORPF P, GOODMAN MW, BURSTEIN WS, NASH NR, BRANN MR, WEINER DM: Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine FI, receptor. Neuropharmaco/ogy (2002) 42:929–940.
- ODA T, MORIKAWA N, SAITO Y, MASUHO Y, MATSUMOTO S: Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. (2000) 275:36781–36786.
- LEURS R, BLANDINA P, TEDFORD C,TIMMERMAN H: Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci. (1998) 19:177–183.
- ROULEAU A. GARBARG X, LIGNEAU C et al.: Bioavailability, antinociceptive and antiinflammatory properties of BP-294, a histamine H3 receptor agonist prodrug. j Pharmacol Exp. Ther. (1997) 281:1085–1094.
- HASHIMOTO T, HARUSAWA S, ARAKI L et al.: A selective human H4-receptor agonist: (-)-2-cyano-1-methyl-3-1(2R,5R)-541H-imidazol-4(5)-ylltetrahydrofuran-2-yllmethylguanidine. J. Med. Chem. (2003) 46:3162–3165.
- GANELLIN CR, LEURQUIN F, PIRIPITSI A et al.: Synthesis of potent non-imidazole histamine H3-receptor antagonists. Arch. Pharm. Pharm. Med. Chem. (1998) 331:395–404.
- KORTE k MYERS J, SHIH NY, EGAN RW, CLARK MA: Characterization and tissue distribution of H3 histamine receptors in guinea pigs by N-a-methylhistamine. Biochem. Biophys. Res. Commun. (1990) 168:979–986.
- WEST RE, ZWEIG A, SHIH NY, SIEGEL MI, EGAN RW, CLARK MA: Identification of two H3-histamine receptor subtypes. MoL Pharmacol (1990) 38:610–613.
- LOVENBERG T, PYATI J, CHANG H, WILSON SJ, ERLANDER MG: Cloning of rat histamine H3 receptor reveals distinct species pharmacological profiles. Pharmacol Exp. Ther. (2000) 293:771–778.
- LIU Q, HORIO Y, FUJIMOTO K, FUKUI H: Does the [3H]-mepyramine binding site represent the histamine H, receptor? Re-examination of the histamine H, receptor with quinine. J. Pharmacol Exp. Ther. (1994) 268:959–964.
Websites
- http://www.iddb3.com/iddb3/iddb3_2/ reports.display?id455978aemplateDrug 86_query_id 5490926 H 3 Histamine Antagonists, Novo Nordisk. IDdb - Drug Report. Thomson Scientific Ltd., London, UK.
- http://www.dailydrugnews.com/Ess/ detail.cfm?Come_FromNoticesMN_ID 69225&StructureYes&FromLas0/020year &ToDateToday&DrugName&Manufac &Section&ThGroup&ContentsABT c/o2D239&TypeComp&TypeInfo&Grou pSec. DailyDrugNews .com Therapeutic Potential of the Histamine H3 Receptor Antagonist ABT-239 (25 April 2005). Prous Science.